ERBB2 and gastric cancer: The publication of subsequent clinical research data, including ORIENT-16,6 RATIONALE-305,25 GEMSTONE-303,26 and KEYNOTE-85927 further solidifies the role of PD-1 blockade combined with chemotherapy as a first-line treatment for HER2-negative advanced gastric cancer patients (Table 4).